Many patients with psoriatic arthritis treated with secukinumab have reduced symptoms and improved quality of life compared with placebo, according to an industry-funded study of more than 2000 patients. 

The posthoc analysis used data from patients with psoriatic arthritis participating in four on-label phase three trials.

US researchers used the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and Outcome Measures in Rheumatology (GRAPPA-OMERACT) to measure improvements in a range of domains, including musculoskeletal disease activity, skin disease activity, pain, physical function, fatigue, and systemic inflammation.

“Among patients treated with secukinumab 300mg, 34.3% and 19.5% achieved complete resolution of swollen and tender joint counts, respectively,” the authors wrote.